XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis

被引：73

作者：

Guo, Yu ^{[1
]}

Xiong, Bing-Hong ^{[2
]}

Zhang, Tao ^{[3
]}

Cheng, Yong ^{[1
]}

Ma, Li ^{[4
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China

[2] Kunming Med Univ, Affiliated Hosp 1, Dept Gastrointestinal & Hernia Surg, Sch Clin Med 1, Kunming, Peoples R China

[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400016, Peoples R China

[4] Third Hosp Mianyang, Dept Emergency, Mianyang, Peoples R China

来源：

CANCER INVESTIGATION | 2016年 / 34卷 / 02期

关键词：

Colorectal cancer; Fluorouracil; Capecitabine; Oxaliplatin; CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; ORAL CAPECITABINE; COLON-CANCER; FLUOROURACIL; LEUCOVORIN; THERAPY; 5-FLUOROURACIL/LEUCOVORIN; SURVIVAL;

D O I：

10.3109/07357907.2015.1104689

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.

引用

页码：94 / 104

页数：11

共 32 条

[11] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer [J].

Ducreux, Michel ;

Bennouna, Jaafar ;

Hebbar, Mohamed ;

Ychou, Marc ;

Lledo, Gerard ;

Conroy, Thierry ;

Adenis, Antoine ;

Faroux, Roger ;

Rebischung, Christine ;

Bergougnoux, Loic ;

Kockler, Leila ;

Douillard, Jean-Yves .

INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (03) :682-690

[12] Bias in meta-analysis detected by a simple, graphical test [J].

Egger, M ;

Smith, GD ;

Schneider, M ;

Minder, C .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634

[13] Potential regional differences for the tolerability profiles of fluoropyrimidines [J].

Haller, Daniel G. ;

Cassidy, Jim ;

Clarke, Stephen J. ;

Cunningham, David ;

Van Cutsem, Eric ;

Hoff, Paulo M. ;

Rothenberg, Mace L. ;

Saltz, Leonard B. ;

Schmoll, Hans-Joachim ;

Allegra, Carmen ;

Bertino, Joseph R. ;

Douillard, Jean-Yves ;

Gustavsson, Bengt G. ;

Milano, Gerard ;

O'Connell, Michael ;

Rustum, Youcef ;

Tabernero, Josep ;

Gilberg, Frank ;

Sirzen, Florin ;

Twelves, Chris .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2118-2123

[14] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study [J].

Hochster, Howard S. ;

Hart, Lowell L. ;

Ramanathan, Ramesh K. ;

Childs, Barrett H. ;

Hainsworth, John D. ;

Cohn, Allen L. ;

Wong, Lucas ;

Fehrenbacher, Louis ;

Abubakr, Yousif ;

Saif, M. Wasif ;

Schwartzberg, Lee ;

Hedrick, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3523-3529

[15] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].

Hoff, PM ;

Ansari, R ;

Batist, G ;

Cox, J ;

Kocha, W ;

Kuperminc, M ;

Maroun, J ;

Walde, D ;

Weaver, C ;

Harrison, E ;

Burger, HU ;

Osterwalder, B ;

Wang, AO ;

Wong, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292

[16] Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer [J].

Hofheinz, R-D ;

Heinemann, V. ;

von Weikersthal, L. F. ;

Laubender, R. P. ;

Gencer, D. ;

Burkholder, I. ;

Hochhaus, A. ;

Stintzing, S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1678-1683

[17] Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J].

Jadad, AR ;

Moore, RA ;

Carroll, D ;

Jenkinson, C ;

Reynolds, DJM ;

Gavaghan, DJ ;

McQuay, HJ .

CONTROLLED CLINICAL TRIALS, 1996, 17 (01) :1-12

[18] Cancer statistics, 2005 [J].

Jemal, A ;

Murray, T ;

Ward, E ;

Samuels, A ;

Tiwari, RC ;

Ghafoor, A ;

Feuer, EJ ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) :10-30

[19] Long-Term Neurotoxicity Effects of Oxaliplatin Added to Fluorouracil and Leucovorin as Adjuvant Therapy for Colon Cancer: Results from National Surgical Adjuvant Breast and Bowel Project Trials C-07 and LTS-01 [J].

Kidwell, Kelley M. ;

Yothers, Greg ;

Ganz, Patricia A. ;

Land, Stephanie R. ;

Ko, Clifford Y. ;

Cecchini, Reena S. ;

Kopec, Jacek A. ;

Wolmark, Norman .

CANCER, 2012, 118 (22) :5614-5622

[20] Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial) [J].

Martoni, Andrea Angelo ;

Pinto, Carmine ;

Di Fabio, Francesca ;

Lelli, Giorgio ;

Rojas Llimpe, Fabiola Lorena ;

Gentile, Anna Lisa ;

Mutri, Vita ;

Ballardini, PierLuigi ;

Giaquinta, Stefania ;

Piana, Edera .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (18) :3161-3168

← 1 2 3 4 →